OWC Pharmaceutical Research Corp, Letter to Shareholders – February 11, 2019

RAMAT GAN, Israel, Feb. 11, 2019 /PRNewswire/ — OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders.

OWC Logo (PRNewsfoto/OWC Pharmaceutical Research Cor)

To our Shareholders,

The last year was a critical year in which we laid the foundations for the sustainable success for our Company. We defined our strategy carefully and consolidated our positioning as a company which undertakes the research and development of fully validated medical products and pharmaceuticals based on cannabis. As a company, we do not want to participate in the undifferentiated cannabis market, as we believe that this will rapidly become commoditized and any short-term value generated will disappear. Whilst the pathway we are taking is longer and more complex, it is our belief that it will deliver genuine medical

... read more at: https://www.biospace.com/article/owc-pharmaceutical-research-corp-letter-to-shareholders-february-11-2019/